2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5318 SWOG S2506 MOZART MZL: A randomized phase II study evaluating mosunetuzumab alone and in combination with either zanubrutinib or polatuzumab vedotin for the treatment of participants with Relapsed/refractory marginal zone lymphoma

Boyu Hu, MD, Gabby Lopez, MS2, Hongli Li, MS3, Michael Leblanc, MD4, Bei Hu, MD5, Joo Song, MD6, Ajay Major, MD, MBA7, Joanna M Rhodes, MD, MSCE8, Narendranath Epperla, MD, MS, FACP9, Jennifer E. Amengual, MD10, Jonathan W. Friedberg, MD11, Sonali Smith, MD, FASCO12
1 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
2 SWOG Statistics and Data Management Center, Seattle, Washington, United States
3 SWOG Statistics and Data Management Center, Seattle, Washington, United States
4 SWOG Statistics and Data Management Center, Seattle, Washington, United States
5 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
6 City of Hope Comprehensive Cancer Center, Duarte, California, United States
7 University of Colorado Cancer Center, Aurora, Colorado, United States
8 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
9 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
10 NYP/Columbia University Medical Irving Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
11 Wilmot Cancer Center at The University of Rochester, Rochester, New York, United States
12 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Background: Despite being the 3rd most common subtype of B-cell non-Hodgkin lymphoma (NHL), marginal zone lymphoma (MZL) remains understudied in the relapsed/refractory (R/R) setting. Prospective randomized trials evaluating the safety and efficacy of new treatments are scarce, and no such studies have been conducted through the North American National Clinical Trials Network (NCTN). Consequently, many FDA approvals and NCCN Guideline recommendations for R/R MZL are based on subgroup analyses involving as few as 24 MZL patients within larger indolent NHL studies, or single-arm phase II studies investigating indefinite-duration therapies. Therefore, the identification of safe, efficacious, and time-limited therapies for R/R MZL remains an unmet clinical need.

Mosunetuzumab (mosun) is a T-cell engaging bispecific antibody (BsAb) targeting CD3 and CD20, which gained FDA approval for the treatment of R/R follicular lymphoma (FL). Mosun is an attractive agent for MZL given comparable sensitivity of MZL and FL to CD20 targeting therapies. Furthermore, mosun’s response-adapted and fixed-duration administration maximizes key treatment goals for R/R MZL, namely preserving quality of life and minimizing treatment toxicities. While the complete response (CR) rate of IV mosun monotherapy for R/R FL was 60%, combining mosun with other targetable pathways in MZL, such as Bruton’s tyrosine kinase (BTK) and CD79b, could increase CR rates and lead to better long-term disease control in R/R MZL.

Study Design and Methods: S2506 MOZART MZL (NCT07638722) is a randomized phase II study sponsored by SWOG/NCTN. Participants are randomized 1:1:1 to the 3 treatment arms: Arm 1) mosun monotherapy, Arm 2) mosun + zanubrutinib (Z), and Arm 3) mosun + polatuzumab vedotin (PV). All participants receive initial subcutaneous mosun step up dosing with 5mg on cycle (C) 1 day (D) 1, 45mg on C1D8, C1D15 and C2D1 and then 45mg every 21 days thereafter; all mosun doses, including the step-up doses, are administered as outpatient. Z (Arm 2) is dosed continuously through each cycle whereas PV (Arm 3) is administered on D1 of C1-C6; both drugs are given at standard doses. A response assessment will occur after 8 cycles of the assigned treatment arm, with those who achieve a CR coming off study treatment while those who achieve a partial response (PR) or stable disease continuing mosun alone (Arms 1 and 3) or mosun + Z (Arm 2) for an additional 9 cycles to complete ~12 months of treatment. Primary objectives of the study are to compare the CR rates of mosun with or without Z (i.e. Arm 2 vs. 1) and mosun with or without PV (i.e. Arm 3 vs. 1). Key secondary objective is to compare the progression-free survival (PFS) between the doublet treatment arms vs. mosun monotherapy (i.e. Arm 2 vs. Arm 1 and Arm 3 vs. Arm 1). The trial also includes patient-reported outcomes and translational science exploratory objectives.

Eligibility: Key inclusion criteria include a diagnosis CD20+ MZL according to the WHO criteria, age 18 years or older, R/R after at least 1 prior line of anti-CD20 directed systemic therapy, and measurable disease per 2014 Lugano Criteria. Participants must meet one criterion for further systemic therapy such as symptomatic or bulky disease, and should not have active CNS disease or known transformation to large B-cell lymphoma. Furthermore, participants cannot have been exposed to prior PV for any reason, but those who have been exposed to prior CD3/CD20 BsAb or BTK inhibitors must have completed treatment 180 days prior to registration and have received a best response of either PR or CR to these therapies.

Statistical Considerations: Based on the prior CR rate observed in R/R FL, mosun monotherapy is estimated to achieve a 50% CR (null hypothesis). Aiming for 75% CR in either of the doublet arms, 123 eligible participants (41 per arm) are required for the primary hypothesis testing by giving the study 81% power and one-sided alpha of 0.075. The trial also includes 3 planned interim analyses for safety, futility and accrual feasibility.

Conclusions: S2506 MOZART MZL was activated August 10, 2026 and is the first study sponsored by the NCTN solely for MZL with all 3 treatment arms having the potential to become safe, efficacious, and time-limited standard-of-care therapies. At the conclusion of S2506, one treatment arm will be carried forward into a future phase III confirmatory study.

Boyu Hu, MD: Genentech - Research Funding; Newave - Research Funding; Caribou Biosciences - Research Funding; Morphosys AG - Research Funding; Lyell Immunopharma - Research Funding; Incyte Corporation - Research Funding; AstraZeneca - Research Funding; Artiva Biotherapeutics - Research Funding; Genentech - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)